Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug 22:5:439.
doi: 10.3389/fmicb.2014.00439. eCollection 2014.

The influence of delivery vectors on HIV vaccine efficacy

Beatrice O Ondondo  1
Affiliations
Review

The influence of delivery vectors on HIV vaccine efficacy

Beatrice O Ondondo. Front Microbiol. .

Abstract

Development of an effective HIV/AIDS vaccine remains a big challenge, largely due to the enormous HIV diversity which propels immune escape. Thus novel vaccine strategies are targeting multiple variants of conserved antibody and T cell epitopic regions which would incur a huge fitness cost to the virus in the event of mutational escape. Besides immunogen design, the delivery modality is critical for vaccine potency and efficacy, and should be carefully selected in order to not only maximize transgene expression, but to also enhance the immuno-stimulatory potential to activate innate and adaptive immune systems. To date, five HIV vaccine candidates have been evaluated for efficacy and protection from acquisition was only achieved in a small proportion of vaccinees in the RV144 study which used a canarypox vector for delivery. Conversely, in the STEP study (HVTN 502) where human adenovirus serotype 5 (Ad5) was used, strong immune responses were induced but vaccination was more associated with increased risk of HIV acquisition than protection in vaccinees with pre-existing Ad5 immunity. The possibility that pre-existing immunity to a highly promising delivery vector may alter the natural course of HIV to increase acquisition risk is quite worrisome and a huge setback for HIV vaccine development. Thus, HIV vaccine development efforts are now geared toward delivery platforms which attain superior immunogenicity while concurrently limiting potential catastrophic effects likely to arise from pre-existing immunity or vector-related immuno-modulation. However, it still remains unclear whether it is poor immunogenicity of HIV antigens or substandard immunological potency of the safer delivery vectors that has limited the success of HIV vaccines. This article discusses some of the promising delivery vectors to be harnessed for improved HIV vaccine efficacy.

Keywords: ALVAC; DNA; HIV-1; MVA; NYVAC; adenovirus; delivery vectors; vaccines.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abbink P., Lemckert A. A., Ewald B. A., Lynch D. M., Denholtz M., Smits S., et al. (2007). Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81, 4654–4663 10.1128/JVI.02696-06 - DOI - PMC - PubMed
    1. Abe S., Okuda K., Ura T., Kondo A., Yoshida A., Yoshizaki S., et al. (2009). Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. J. Gene Med. 11, 570–579 10.1002/jgm.1332 - DOI - PMC - PubMed
    1. Afolabi M. O., Ndure J., Drammeh A., Darboe F., Mehedi S. R., Rowland-Jones S. L., et al. (2013). A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants. PLoS ONE 8:e78289 10.1371/journal.pone.0078289 - DOI - PMC - PubMed
    1. Albarran Y. C. A., de la Garza A., Cruz Quiroz B. J., Vazquez Zea E., Diaz Estrada I., Mendez Fuentez E., et al. (2007). MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. BioDrugs 21, 47–59 10.2165/00063030-200721010-00006 - DOI - PubMed
    1. Albu D. I., Jones-Trower A., Woron A. M., Stellrecht K., Broder C. C., Metzger D. W. (2003). Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins. J. Virol. 77, 5589–5597 10.1128/JVI.77.10.5589-5597.2003 - DOI - PMC - PubMed